PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2 - EXHIBIT 99.2

Attached files

file	filename
8-K - FORM 8-K - PDL BIOPHARMA, INC.	pdl_8k-090612.htm
EX-99.1 - EXHIBIT 99.1 - PDL BIOPHARMA, INC.	ex99-1.htm

Exhibit 99.2

Royalty Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2012	23,215	41,670	25,955	-		90,841
2011	22,283	41,967	23,870	22,886		111,006
2010	16,870	44,765	29,989	24,922		116,547
2009	13,605	35,161	21,060	15,141		84,966
2008	9,957	30,480	19,574	12,394		72,405
2007	8,990	21,842	17,478	9,549		57,859
2006	10,438	15,572	15,405	12,536		53,952

Herceptin	Q1	Q2	Q3	Q4	Total
2012	25,702	44,628	30,433	-		100,763
2011	25,089	42,209	31,933	21,812		121,042
2010	23,402	38,555	27,952	25,441		115,350
2009	16,003	32,331	26,830	18,615		93,779
2008	14,092	34,383	28,122	20,282		96,880
2007	19,035	28,188	22,582	14,802		84,608
2006	15,142	19,716	21,557	20,354		76,769

Lucentis	Q1	Q2	Q3	Q4	Total
2012	10,791	27,938	12,552	-		51,280
2011	8,878	24,313	12,157	10,750		56,099
2010	7,220	19,091	10,841	8,047		45,198
2009	4,621	12,863	8,123	6,152		31,759
2008	3,636	11,060	7,631	4,549		26,876
2007	2,931	6,543	6,579	3,517		19,570
2006	-	-	289	3,335		3,624

Xolair	Q1	Q2	Q3	Q4	Total
2012	5,447	8,609	6,504	-		20,560
2011	4,590	7,621	5,916	5,823		23,949
2010	3,723	6,386	4,980	4,652		19,741
2009	2,665	5,082	4,085	3,722		15,553
2008	1,488	4,866	3,569	2,927		12,850
2007	1,684	3,942	3,332	2,184		11,142
2006	2,263	2,969	3,041	2,495		10,768

Perjeta	Q1	Q2	Q3	Q4	Total
2012	-	-	58	-		58

Tysabri	Q1	Q2	Q3	Q4	Total
2012	11,233	12,202	11,749	-		35,184
2011	9,891	10,796	11,588	11,450		43,725
2010	8,791	8,788	8,735	9,440		35,754
2009	6,656	7,050	7,642	8,564		29,912
2008	3,883	5,042	5,949	6,992		21,866
2007	839	1,611	2,084	2,836		7,370
2006	-	-	-	237		237

Actemra	Q1	Q2	Q3	Q4	Total
2012	1,705	2,074	2,145	-		5,923
2011	913	1,136	1,401	1,460		4,910
2010	1,587	237	315	688		2,827
2009	585	537	909	1,197		3,228
2008	44	-	146	369		559
2007	32	-	-	17		49
2006	-	-	-	-		-

* As reported to PDL by its licensees
Totals may not sum due to rounding

Reported Net Sales Revenue by Product ($ in 000's) *

Avastin	Q1	Q2	Q3	Q4	Total
2012	1,502,757	1,573,727	1,551,327	-		4,627,810
2011	1,597,461	1,582,705	1,581,095	1,469,994		6,231,255
2010	1,506,788	1,596,892	1,594,707	1,646,218		6,344,605
2009	1,345,487	1,295,536	1,439,730	1,514,053		5,594,806
2008	980,715	1,084,930	1,180,427	1,239,382		4,485,454
2007	678,068	746,587	797,013	875,084		3,096,752
2006	439,318	516,052	570,551	592,897		2,118,817

Herceptin	Q1	Q2	Q3	Q4	Total
2012	1,515,255	1,625,313	1,663,695	-		4,804,264
2011	1,391,568	1,559,975	1,642,898	1,432,771		6,027,211
2010	1,270,846	1,349,512	1,300,934	1,409,310		5,330,602
2009	1,210,268	1,133,993	1,226,435	1,278,626		4,849,323
2008	1,105,426	1,195,215	1,211,982	1,186,806		4,699,428
2007	891,761	949,556	979,602	1,015,033		3,835,952
2006	529,585	659,719	761,099	803,576		2,753,979

Lucentis	Q1	Q2	Q3	Q4	Total
2012	1,079,092	1,086,543	1,097,541	-		3,263,176
2011	887,757	943,418	1,052,809	1,075,015		3,958,999
2010	721,967	698,890	745,376	804,684		2,970,917
2009	462,103	469,736	555,296	615,212		2,102,347
2008	363,615	393,682	460,167	454,922		1,672,386
2007	224,820	219,579	299,995	322,300		1,066,695
2006	-	-	10,689	157,742		168,431

Xolair	Q1	Q2	Q3	Q4	Total
2012	310,234	314,638	347,796	-		972,669
2011	267,754	277,642	310,874	314,911		1,171,182
2010	228,859	225,878	251,055	263,389		969,179
2009	184,669	181,086	211,006	219,693		796,454
2008	137,875	169,521	177,179	183,753		668,329
2007	129,172	130,700	144,250	147,754		551,876
2006	95,241	99,354	112,608	118,002		425,204

Perjeta	Q1	Q2	Q3	Q4	Total
2012	-	-	5,080	-		5,080

Tysabri	Q1	Q2	Q3	Q4	Total
2012	374,430	401,743	391,623	-		1,167,796
2011	329,696	356,876	388,758	381,618		1,456,948
2010	293,047	287,925	293,664	316,657		1,191,292
2009	221,854	229,993	257,240	285,481		994,569
2008	129,430	163,076	200,783	233,070		726,359
2007	30,468	48,715	71,972	94,521		245,675
2006	-	-	-	7,890		7,890

Actemra	Q1	Q2	Q3	Q4	Total
2012	56,662	66,624	71,505	-		194,791
2011	30,433	35,370	46,709	48,671		161,183
2010	52,908	5,405	10,493	22,919		91,725
2009	19,504	17,920	30,313	39,888		107,625
2008	1,452	1,377	5,981	12,305		21,115
2007	-	-	-	1,137		1,137
2006	-	-	-	-		-

* As reported to PDL by its licensees
Totals may not sum due to rounding

Manufacturing Location & Sales - Genentech / Roche & Novartis ($ in 000's) *

Avastin Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	719,967		688,966		684,878		652,824		724,483		679,914
US Made & ex-US Sold	548,710		587,975		375,830		448,037		532,979		428,976
ex-US Made & Sold	314,028		304,155		409,286		401,896		316,265		442,437
Total	1,582,705		1,581,095		1,469,994		1,502,757		1,573,727		1,551,327
US Made & Sold	45	%	44	%	47	%	43	%	46	%	44	%
US Made & ex-US Sold	35	%	37	%	26	%	30	%	34	%	28	%
ex-US Made & Sold	20	%	19	%	28	%	27	%	20	%	29	%

Herceptin Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	442,903		445,395		453,168		456,920		497,109		503,612
US Made & ex-US Sold	642,670		495,086		612,908		523,353		466,477		545,625
ex-US Made & Sold	474,402		702,416		366,695		534,982		661,727		614,459
Total	1,559,975		1,642,898		1,432,771		1,515,255		1,625,313		1,663,695
US Made & Sold	28	%	27	%	32	%	30	%	31	%	30	%
US Made & ex-US Sold	41	%	30	%	43	%	35	%	29	%	33	%
ex-US Made & Sold	30	%	43	%	26	%	35	%	41	%	37	%

Lucentis Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	409,674		422,335		428,884		433,428		412,131		385,746
US Made & ex-US Sold	533,745		630,474		646,131		645,665		674,411		711,795
ex-US Made & Sold	-		-		-		-		-		-
Total	943,418		1,052,809		1,075,015		1,079,092		1,086,543		1,097,541
US Made & Sold	43	%	40	%	40	%	40	%	38	%	35	%
US Made & ex-US Sold	57	%	60	%	60	%	60	%	62	%	65	%
ex-US Made & Sold	0	%	0	%	0	%	0	%	0	%	0	%

Xolair Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	167,608		184,837		188,728		185,505		193,600		211,702
US Made & ex-US Sold	-		-		-		-		-		-
ex-US Made & Sold	110,034		126,037		126,184		124,729		121,039		136,094
Total	277,642		310,874		314,911		310,234		314,638		347,796
US Made & Sold	60	%	59	%	60	%	60	%	62	%	61	%
US Made & ex-US Sold	0	%	0	%	0	%	0	%	0	%	0	%
ex-US Made & Sold	40	%	41	%	40	%	40	%	38	%	39	%

Perjeta Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	-		-		-		-		-		5,080
US Made & ex-US Sold	-		-		-		-		-		-
ex-US Made & Sold	-		-		-		-		-		-
Total	-		-		-		-		-		5,080

Total Sales	2011 - Q2		2011 - Q3		2011 - Q4		2012 - Q1		2012 - Q2		2012 - Q3
US Made & Sold	1,740,152		1,741,534		1,755,657		1,728,678		1,827,323		1,786,053
US Made & ex-US Sold	1,725,125		1,713,535		1,634,869		1,617,054		1,673,867		1,686,395
ex-US Made & Sold	898,464		1,132,608		902,165		1,061,607		1,099,031		1,192,990
Total	4,363,741		4,587,677		4,292,691		4,407,339		4,600,221		4,665,438
US Made & Sold	40	%	38	%	41	%	39	%	40	%	38	%
US Made & ex-US Sold	40	%	37	%	38	%	37	%	36	%	36	%
ex-US Made & Sold	21	%	25	%	21	%	24	%	24	%	26	%

* As reported to PDL by its licensees
Totals may not sum due to rounding

PDL BIOPHARMA, INC. - FORM 8-K - EX-99.2 - EXHIBIT 99.2 - September 6, 2012

Attached files

PDL BIOPHARMA, INC. Reports